31 August - 04 September 2019, Paris - France

Session Details

Poster Session 2: Atrial fibrillation pathophysiology and mechanisms
Sun 01 Sep 08:30 - 12:30 European Society of Cardiology Poster Session, Abstract-based Programme Posters - Poster Area
Learning Objectives: Posters are on display from 08:30 – 12:30. Presenters will be by their poster during the coffee break from 10:05 and 10:55 for posters viewing time.

Access slides, videos, reports online via ESC Congress 365 Other resources

List of Presentations

Related documents
08:30P1888Autoantiboides to muscarinic m2 cholinoceptors in patients with paroxysmal atrial fibrillationEkaterina MIRONOVA (Moscow, Russian Federation)
08:30P1889Quantitative global proteomics and lysine acetylome analysis of changes in left atrial appendage tissue from valvular heart disease patients with atrial fibrillationTao TU (, China)
08:30P1890Pioglitazone inhibits diabetes-induced atrial mitochondrial oxidative stress and improves mitochondrial biogenesis, dynamics and function through the PGC-1 signaling pathwayGary TSE (Shatin, Hong Kong)
08:30P1891CD8+CD28null T lymphocytes are associated with the development of atrial fibrillation after elective cardiac surgeryNiema KAZEM (Vienna, Austria)
08:30P1892Asymmetric and symmetric dimethylarginine in atrial fibrillation progression and recurrencePetra BUETTNER (Leipzig, Germany)
08:30P1894Serum light-chain neurofilament is associated with brain atrophy in patients with atrial fibrillationStefanie AESCHBACHER (Basel, Switzerland)
08:30P1895Predictors of left atrial thrombosis in patients undergoing planned electrical cardioversion of atrial fibrillation treated with direct anticoagulantVeronica LIO (Motta Di Livenza, Italy)
08:30P1896Single-procedure success-rate of pulmonary vein isolation using point-by-point tagging lesions algorithm based on contact force technology: preliminary results of the multicentric SMOP studyStefano CORNARA (Pavia, Italy)
08:30P1897Prescription of guideline recommended oral anticoagulation and reasons reported for non-use of OAC in patients with atrial fibrillation: Data from the German AFNET-2 RegistryMichael NAEBAUER (Munich, Germany)